Hypertension - Boise ID (Clinical Trial # 14234)
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials. 
|
 |
 |
| City: |
|
Boise |
| State: |
|
ID |
| Zip Code: |
|
83704 |
| Study summary: |
|
A multicenter, randomized, double blind, placebo controlled, 8-week study to evaluate the safety and efficacy of nebivolol and valsartan given as a fixed-dose combination in patients with stage 1 or 2 essential hypertension. |
| Qualified participants must: |
|
• Patients diagnosed with stage 1 or stage 2 essential hypertension
•
Be currently being treated for hypertension with at least 1 documented DBP value ≥ 90 and < 110 mm Hg in their medical history or at a recent time during prescreening
•
Be newly diagnosed with essential hypertension who have never received treatment
•
Have a mean sitting DBP > 95 and < 110 mm Hg at Screening (Visit 1)
•
Been previously diagnosed and who have not received antihypertensive medications for at least 4 weeks prior to Screening (Visit 1) must have a mean sitting DBP > 95 and < 110 mm Hg at screening (Visit 1)
•
Have a sitting pulse rate of at least 55 bpm at Screening
|
| Participants may receive: |
|
Compensation for time and travel |
|
|
|
| Clinic Profile: |
|
View Clinic Profile |
|
Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials or take the Participation Quiz to find out if you are a good candidate for clinical trial participation.